

Temporary Change in Status for Platelet Aggregation Inhibitors Drug Class Effective May 28

Background:

HHSC has been informed of a drug shortage for Aggrenox in the Platelet Aggregation Inhibitors drug class. VDP received reports of a shortage and the FDA notifications website indicates the manufacturer will not supply the market with Aggrenox capsules after June 11.

Key Details:

In response to the reported shortage, VDP temporarily removed the non-preferred status from the generic formulations of dipyridamole/aspirin. The NDCs involved in this change are listed in the attachment and changes are effective May 28.

These changes will allow providers to prescribe for these drugs without requiring a PDL prior authorization and allow continued access to necessary medication for clients. Changes will be reflected on daily formulary files.

VDP will provide further announcements regarding future PDL status changes for these NDCs because of the discontinuation of the Aggrenox brand by the manufacturer, Boehringer Ingelheim Pharmaceuticals.

Resources:

Aggrenox generics NDCs.xlsx

Contact:

vdp-formulary@hhsc.state.tx.us

NDC	Label Name
43598033960	ASPIRIN-DIPYRIDAM ER 25-200 MG
49884000702	ASPIRIN-DIPYRIDAM ER 25-200 MG
62559085060	ASPIRIN-DIPYRIDAM ER 25-200 MG
65162059606	ASPIRIN-DIPYRIDAM ER 25-200 MG
70436009205	ASPIRIN-DIPYRIDAM ER 25-200 MG
68462040560	ASPIRIN-DIPYRIDAM ER 25-200 MG